journal article·2024-09Open access

Cu+/Ca2+ Dual‐Overload Strategy Assisted by Metabolic‐Symbiotic‐Destruction for Tumor Apoptosis and Tumor Immune Activation

Jiahui Yan, Haoyu Chen, Carlos F. Guimarães, Rui L. Reis, Zhihua Zhu, Tianyi Wang, Fenglan Zhang, Yaqian Lv, Qihui Zhou, Xiaoying Kong, Jinsheng Shi

Advanced Functional Materials· Volume 34· Issue 39

Abstract

Abstract Ion interference including copper (Cu+)/calcium (Ca2+) overload activate cell‐specific death channels, damage mitochondria and disrupt cellular homeostasis, showing great potential in anti‐tumor therapy. However, the complex metabolic environment and the powerful self‐protection of tumors cause clinical failure of ion interference. Thus, metabolic disruption is expected an innovative strategy for the enhancement of ion interference. Herein, CuS‐α‐CHCA&penthiopyrad@CaCO3‐RGD nanoparticles (CCPCR NPs) are prepared to provide a Cu+/Ca2+ dual‐overload anti‐tumor therapy assisted by metabolic‐symbiosis‐destruction strategy, realizing the collapse of tumor self‐protection. Specifically, precise CuS and CaCO3 delivery triggered irreversible Cu+/Ca2+ dual‐overload and reactive oxygen species (ROS) attack toward 4T1 cells. Meanwhile, α‐CHCA and penthiopyrad disturbed the metabolic symbiotic environment by disrupting the TCA cycle and preventing lactate efflux to aggravate intracellular acidosis and promote Fenton‐like reaction of Cu+, enhancing the sensitivity of tumor cells to copper death and Ca2+ overload. Further, aided by the metabolism of symbiosis, the destroyed tumor cells further activate the polarization of M1 macrophages and the maturation and antigen cross‐presentation of dendritic cells (DCs), which further eliminate tumor cells. In summary, an amplified anti‐tumor dual‐ion interference strategy assisted by metabolic symbiotic destruction is established, which is of great significance in improving the clinical effect of ion therapy for tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Adenosine and Purinergic Signaling · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Qingdao Municipal Hospital University of Health and Rehabilitation Sciences Qingdao 266071 China

College of Chemistry and Pharmaceutical Sciences Qingdao Agricultural University Qingdao 266109 China

3B's Research Group‐Research Institute on Biomaterials Biodegradables and Biomimetics Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine University of Minho Parque de Ciência e Tecnologia, Zona Industrial da Gandra – Avepark, Barco Guimarães 4805‐017 Portugal

ICVS/3B's – Portuguese Government Associate Laboratory University of Minho Guimarães/Braga 4800‐058 Portugal

Traditional Chinese Medicine Department Chengyang District People's Hospital Qingdao 266100 China

School of Veterinary Medicine Qingdao Agricultural University Qingdao 266100 China

Qingdao Key Laboratory of Materials for Tissue Repair and Rehabilitation School of Rehabilitation Sciences and Engineering University of Health and Rehabilitation Sciences Qingdao 266113 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province

References (45)

Show source-provided references
1. 10.1016/j.cej.2022.14122710.1016/j.cej.2022.141227 ↗
2. 10.1002/adfm.20230094110.1002/adfm.202300941 ↗
3. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
4. 10.1126/science.abo395910.1126/science.abo3959 ↗
5. 10.1038/s41467-022-35515-810.1038/s41467-022-35515-8 ↗
6. 10.1002/adfm.20220501310.1002/adfm.202205013 ↗
7. 10.1002/adma.20220473310.1002/adma.202204733 ↗
8. 10.1002/adma.20200806510.1002/adma.202008065 ↗
9. Liu Z. C. · J. Exp. Clin. Cancer Res. · 2020 · 39
10. Jiang Y. P. · Adv. Healthcare Mater. · 2021 · 10 · 1
11. 10.1016/j.biomaterials.2023.12228410.1016/j.biomaterials.2023.122284 ↗
12. 10.1016/j.arr.2023.10195110.1016/j.arr.2023.101951 ↗
13. 10.1172/JCI12428310.1172/JCI124283 ↗
14. 10.1016/j.jhep.2017.05.02310.1016/j.jhep.2017.05.023 ↗
15. 10.1016/j.jhazmat.2021.12602510.1016/j.jhazmat.2021.126025 ↗
16. 10.1021/acsnano.2c1083010.1021/acsnano.2c10830 ↗
17. 10.1016/j.cclet.2023.10843410.1016/j.cclet.2023.108434 ↗
18. 10.1002/advs.20220744810.1002/advs.202207448 ↗
19. 10.1002/adhm.20220310610.1002/adhm.202203106 ↗
20. 10.1002/smll.20220693610.1002/smll.202206936 ↗
21. 10.1021/acsnano.1c0789310.1021/acsnano.1c07893 ↗
22. 10.1016/j.cej.2023.14267510.1016/j.cej.2023.142675 ↗
23. 10.1021/acsnano.2c0733810.1021/acsnano.2c07338 ↗
24. 10.1016/j.biomaterials.2021.12088510.1016/j.biomaterials.2021.120885 ↗
25. 10.1002/adma.20210730010.1002/adma.202107300 ↗
26. 10.1021/acsnano.1c0917110.1021/acsnano.1c09171 ↗
27. 10.1021/acsnano.1c0545110.1021/acsnano.1c05451 ↗
28. 10.1002/adma.20200224610.1002/adma.202002246 ↗
29. 10.1002/adhm.20190019210.1002/adhm.201900192 ↗
30. 10.1186/s13045-022-01392-310.1186/s13045-022-01392-3 ↗
31. 10.1016/j.ccr.2023.21533210.1016/j.ccr.2023.215332 ↗
32. 10.1016/j.biomaterials.2020.12061410.1016/j.biomaterials.2020.120614 ↗
33. 10.1007/s40820-022-00894-610.1007/s40820-022-00894-6 ↗
34. Harjes U. · Nat. Rev. Cancer · 2017 · 17 · 453
35. 10.1158/0008-5472.CAN-20-047110.1158/0008-5472.CAN-20-0471 ↗
36. 10.1016/j.it.2022.10.00510.1016/j.it.2022.10.005 ↗
37. 10.1021/acs.nanolett.1c0479710.1021/acs.nanolett.1c04797 ↗
38. 10.1002/advs.20220329210.1002/advs.202203292 ↗
39. 10.1021/jacs.7b1121210.1021/jacs.7b11212 ↗
40. 10.1158/0008-5472.CAN-15-263710.1158/0008-5472.CAN-15-2637 ↗
41. 10.1016/j.cej.2023.14456310.1016/j.cej.2023.144563 ↗
42. 10.1126/sciadv.abc437310.1126/sciadv.abc4373 ↗
43. Zheng Y. · Adv. Funct. Mater. · 2021 · 32
44. 10.1021/ja902197v10.1021/ja902197v ↗
45. 10.1016/j.cej.2021.13065210.1016/j.cej.2021.130652 ↗